HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy-Reference-Cited by-同舟云学术

HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy

Published:2022-05-02 Issue:9 Volume:132 Page:
ISSN:1558-8238
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Salman Shaima,Meyers David J.^ORCID,Wicks Elizabeth E.^ORCID,Lee Sophia N.,Datan Emmanuel,Thomas Aline M.^ORCID,Anders Nicole M.,Hwang Yousang,Lyu Yajing,Yang Yongkang,Jackson Walter,Dordai Dominic,Rudek Michelle A.^ORCID,Semenza Gregg L.^ORCID

Funder

American Cancer Society

Armstrong Family Foundation

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/156774/files/pdf

Reference97 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Comparison of hepatocellular carcinoma in Eastern versus Western populations

3. Hepatocellular Carcinoma

4. Hepatocellular carcinoma: a review

5. Hepatocellular carcinoma

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical investigation of hypoxia-inducible factors: getting there;Journal of Clinical Investigation;2024-02-01

2. New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma—Today and Tomorrow;International Journal of Molecular Sciences;2024-01-25

3. Hypoxia-Induced Signaling in Gut and Liver Pathobiology;Annual Review of Pathology: Mechanisms of Disease;2024-01-24

4. Associations between HIFs and tumor immune checkpoints: mechanism and therapy;Discover Oncology;2024-01-02

5. Targeting hypoxia-inducible factors: therapeutic opportunities and challenges;Nature Reviews Drug Discovery;2023-12-20